AVTX Avalo Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AVTX

Price (delayed)

$14.36

Market cap

$14.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$114

Enterprise value

$7.43M

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of ...

Highlights
The debt has dropped by 100% year-on-year
The EPS has soared by 89% YoY and by 82% from the previous quarter
The equity has soared by 167% YoY but it has plunged by 50% from the previous quarter
Avalo Therapeutics's quick ratio has soared by 141% YoY but it has decreased by 16% from the previous quarter
The company's gross profit has shrunk by 96% YoY
AVTX's revenue has shrunk by 89% YoY and by 14% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cerecor.com
Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of AVTX
Market
Shares outstanding
1.03M
Market cap
$14.85M
Enterprise value
$7.43M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.58
Price to sales (P/S)
5.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.86
Earnings
Revenue
$1.92M
EBIT
-$28.11M
EBITDA
-$27.96M
Free cash flow
-$30.81M
Per share
EPS
-$114
Free cash flow per share
-$38.44
Book value per share
$9.11
Revenue per share
$2.4
TBVPS
$13.09
Balance sheet
Total assets
$20.99M
Total liabilities
$13.69M
Debt
$0
Equity
$7.3M
Working capital
$3.78M
Liquidity
Debt to equity
0
Current ratio
1.82
Quick ratio
1.64
Net debt/EBITDA
0.27
Margins
EBITDA margin
-1,453%
Gross margin
33.3%
Net margin
-1,639.5%
Operating margin
-1,421.6%
Efficiency
Return on assets
-113.9%
Return on equity
-1,439.9%
Return on invested capital
N/A
Return on capital employed
-171.7%
Return on sales
-1,461.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVTX stock price

How has the Avalo Therapeutics stock price performed over time
Intraday
-9.69%
1 week
-9.91%
1 month
-11.96%
1 year
-97.99%
YTD
57.8%
QTD
-33.98%

Financial performance

How have Avalo Therapeutics's revenue and profit performed over time
Revenue
$1.92M
Gross profit
$640,000
Operating income
-$27.35M
Net income
-$31.54M
Gross margin
33.3%
Net margin
-1,639.5%
The company's gross profit has shrunk by 96% YoY
AVTX's revenue has shrunk by 89% YoY and by 14% QoQ
Avalo Therapeutics's gross margin has plunged by 59% YoY
AVTX's operating income is up by 27% YoY and by 4.2% QoQ

Growth

What is Avalo Therapeutics's growth rate over time

Valuation

What is Avalo Therapeutics stock price valuation
P/E
N/A
P/B
1.58
P/S
5.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.86
The EPS has soared by 89% YoY and by 82% from the previous quarter
The equity has soared by 167% YoY but it has plunged by 50% from the previous quarter
AVTX's revenue has shrunk by 89% YoY and by 14% QoQ
The P/S is 78% lower than the 5-year quarterly average of 27.1

Efficiency

How efficient is Avalo Therapeutics business performance
The ROS has contracted by 15% from the previous quarter
Avalo Therapeutics's ROA has decreased by 12% YoY and by 6% from the previous quarter

Dividends

What is AVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVTX.

Financial health

How did Avalo Therapeutics financials performed over time
AVTX's total assets is 53% greater than its total liabilities
AVTX's current ratio has surged by 146% year-on-year but it is down by 14% since the previous quarter
Avalo Therapeutics's quick ratio has soared by 141% YoY but it has decreased by 16% from the previous quarter
The debt is 100% smaller than the equity
The equity has soared by 167% YoY but it has plunged by 50% from the previous quarter
The company's debt to equity has surged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.